Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care's Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.
Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care’s Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.
Kimberly Shafer-Weaver, PhD, explained that in order to keep providers and patients more aware of the latest developments, there needs to be a better outreach effort at meetings and other venues to educate people about immunotherapists and how they can be used.
Nomogram Aids Early Detection of Myasthenic Crisis Risk
August 19th 2025Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More